Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | FABP7 | O15540 | 1/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | KLK7 | P49862 | 1/20 | 0.37 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13198696 | 1.00 | CPB1 (0.43) | CPB1CTSLKMT2AL3MBTL1SYK | |
| SCHEMBL10119907 | 0.91 | FABP7 (0.44) | CPB1CTSLKMT2AL3MBTL1SYK | |
| SCHEMBL13198690 | 0.91 | FABP7 (0.44) | CPB1CTSLKMT2AL3MBTL1SYK | |
| SCHEMBL10119909 | 0.90 | CPB1 (0.48) | CPB1CTSLKMT2AL3MBTL1SYK | |
| SCHEMBL10119906 | 0.90 | CPB1 (0.48) | CPB1CTSLKMT2AL3MBTL1SYK | |
| SCHEMBL13198694 | 0.90 | CPB1 (0.48) | CPB1CTSLKMT2AL3MBTL1SYK | |
| SCHEMBL22617362 | 0.81 | CPB1 (0.54) | CPB1CTSLKMT2AL3MBTL1SYK | |
| SCHEMBL14827596 | 0.81 | FABP7 (0.48) | KMT2AL3MBTL1FABP7FABP5TSHR | |
| SCHEMBL8691884 | 0.78 | SYK (0.50) | CPB1CTSLKMT2AL3MBTL1SYK | |
| SCHEMBL8691889 | 0.78 | SYK (0.50) | CPB1CTSLKMT2AL3MBTL1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130081999-A1 | Bridged Macrocyclic Module Compositions | WHITEFORD JEFFERY A (US) | 2013-04-04 | — | — | US | disclosed |
| US-8110679-B2 | Nanofilm and membrane compositions | COVALENT PARTNERS LLC (US) | 2012-02-07 | — | — | US | disclosed |
| US-7595368-B2 | Nanofilm compositions with polymeric components | COVALENT PARTNERS, LLC (US) | 2009-09-29 | — | — | US | disclosed |
| US-20090114596-A1 | NANOFILM AND MEMBRANE COMPOSITIONS | COVALENT PARTNERS LLC | 2009-05-07 | — | — | US | disclosed |
| US-7432371-B2 | Nanofilm and membrane compositions | COVALENT PARTNERS, LLC (US) | 2008-10-07 | — | — | US | disclosed |
| US-7368564-B2 | Bridged macrocyclic module compositions | COVALENT PARTNERS, LLC (US) | 2008-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130081999-A1 | Bridged Macrocyclic Module Compositions | SBDS, NCL, INTS6 | CPB1 1531/4885CTSL 1353/4885KMT2A 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.